South Korean consortium to produce 100 million doses of Russia's Sputnik V vaccine per month

SEOUL: South Korea's Huons Global said on Friday (Apr 16) that it will lead a consortium to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine per month as Moscow ramps up production for supplies abroad.

The announcement comes after South Korean biotech firm GL Rapha signed a deal with Russia's sovereign wealth fund late last year to make more than 150 million doses of Sputnik V per year.

Huons said the consortium will begin producing sample batches in August and respond flexibly to supply demands from the Russian Direct Investment Fund (RDIF).

The consortium includes three other local companies - Prestige BioPharma, Humedix and Boran Pharma - which will build a new production facility, Huons said in a statement.

READ: Kremlin says pressure on countries to reject Russia's Sputnik V vaccine is unprecedented

READ: India's Gland Pharma to make up to 252 million Sputnik V COVID-19 vaccine doses

Shares in Huons Global jumped 29.8 per cent to their daily limit on Friday morning trade, versus a flat wider market.

India's ambassador to Moscow on Friday said deliveries of Russia's Sputnik V coronavirus vaccine to India were expected to begin before the end of April, after Indian regulators approved the shot for use on Monday.

The European Medicines Agency (EMA) is conducting a rolling review of the Russian vaccine as many European countries seek to ramp up inoculation programmes that have been hampered by delivery delays.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram​​​​​​